MTHFD2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10387(MTHFD2 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P10387(MTHFD2 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The MTHFD2 (methylenetetrahydrofolate dehydrogenase 2) antibody is a critical tool for studying the mitochondrial folate-mediated one-carbon metabolism pathway. MTHFD2 is a bifunctional enzyme that catalyzes the NAD+-dependent dehydrogenation of methylenetetrahydrofolate (CH2-THF) to methenyl-THF and its subsequent cyclohydrolase activity to form formyl-THF. This enzyme plays a pivotal role in generating one-carbon units essential for purine and thymidylate synthesis, supporting rapid cell proliferation in cancers and developing tissues.

MTHFD2 is overexpressed in many cancers, including breast, lung, and colorectal malignancies, where its activity is linked to tumor growth, poor prognosis, and chemoresistance. Its selective expression in proliferating cells makes it a promising therapeutic target. Researchers use MTHFD2 antibodies primarily for detecting protein expression levels via Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). These applications help elucidate its subcellular localization (mitochondrial), tissue distribution, and correlation with disease progression.

Additionally, MTHFD2 antibodies are employed in functional studies to explore metabolic dependencies in cancer cells and evaluate inhibitors targeting this enzyme. Validating antibody specificity is crucial due to homology with its cytosolic counterpart, MTHFD1. Overall, MTHFD2 antibodies are vital for advancing research into cancer metabolism, biomarker discovery, and the development of targeted therapies.